{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T16:47:59Z","timestamp":1782060479842,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-02\/85"],"award-info":[{"award-number":["Z-02\/85"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-2\/96"],"award-info":[{"award-number":["Z-2\/96"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA) is a central target for prostate cancer theranostics. Androgen receptor (AR) signaling has been implicated in regulating PSMA expression; however, whether different modes of AR pathway inhibition uniformly translate into enhanced functional radioligand uptake, particularly for therapeutic applications, remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      AR-positive (LNCaP, C4-2) and AR-negative (PC3 PSMA\u2009+) prostate cancer models were investigated; parental PC3 cells served as PSMA-negative controls. Cells were treated with the direct AR antagonists enzalutamide and apalutamide or with the androgen biosynthesis inhibitor abiraterone. PSMA surface expression was quantified by flow cytometry. Functional uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 and [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA I&amp;T was assessed by gamma counting. Glucose metabolism was evaluated using [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake, and PSA secretion was measured as a pharmacodynamic readout of AR pathway inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Direct AR antagonism significantly increased PSMA surface expression in AR-positive models and translated into enhanced uptake of the therapeutic radioligand [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA I&amp;T, with particularly pronounced effects in the castration-resistant C4-2 model. Diagnostic tracer uptake was also increased, though less consistently across models. In contrast, abiraterone did not induce consistent functional enhancement of radioligand accumulation despite PSMA upregulation in selected settings. AR-negative PC3 PSMA\u2009+\u2009cells exhibited stable baseline PSMA expression but showed no significant changes in PSMA levels or radioligand uptake following AR antagonist treatment. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG uptake was reduced under AR inhibition in AR-positive models, indicating that enhanced PSMA-targeted uptake was not driven by global metabolic activation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Direct AR antagonism enhances functional PSMA availability and increases short-term uptake of PSMA-targeted radioligands in AR-positive prostate cancer models. These findings provide mechanistic support for AR-mediated modulation of PSMA-targeted radioligand delivery and warrant further translational investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-026-02118-4","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T16:07:41Z","timestamp":1782058061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-9849","authenticated-orcid":false,"given":"Philipp E.","family":"Hartrampf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Hasenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Rogoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Kalogirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"2118_CR1","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"CE Massie","year":"2011","unstructured":"Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L et al (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30:2719\u20132733. https:\/\/doi.org\/10.1038\/emboj.2011.158","journal-title":"EMBO J"},{"key":"2118_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mce.2011.09.046","volume":"360","author":"SM Green","year":"2012","unstructured":"Green SM, Mostaghel EA, Nelson PS (2012) Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 360:3\u201313. https:\/\/doi.org\/10.1016\/j.mce.2011.09.046","journal-title":"Mol Cell Endocrinol"},{"key":"2118_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","volume":"59","author":"DS O'Keefe","year":"2018","unstructured":"O\u2019Keefe DS, Bacich DJ, Huang SS, Heston WDW (2018) A perspective on the evolving story of PSMA Biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med 59:1007\u20131013. https:\/\/doi.org\/10.2967\/jnumed.117.203877","journal-title":"J Nucl Med"},{"key":"2118_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"2118_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC et al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet (London, England) 397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet (London, England)"},{"key":"2118_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf338","author":"RR McKay","year":"2025","unstructured":"McKay RR, Nazari SS, Elliott A, Ribeiro JR, Rose BS, Barata PC et al (2025) Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf338","journal-title":"Oncologist"},{"key":"2118_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031046","author":"U Sommer","year":"2022","unstructured":"Sommer U, Siciliano T, Ebersbach C, Beier AK, Stope MB, J\u00f6hrens K et al (2022) Impact of androgen receptor activity on prostate-specific membrane antigen expression in prostate cancer cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031046","journal-title":"Int J Mol Sci"},{"key":"2118_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147431","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska M, Fragoso Costa P, Eiber M, Klose JM, Wosniack J, Reis H et al (2021) Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22147431","journal-title":"Int J Mol Sci"},{"key":"2118_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/pros.23522","volume":"78","author":"B Kranzb\u00fchler","year":"2018","unstructured":"Kranzb\u00fchler B, Salemi S, Umbricht CA, M\u00fcller C, Burger IA, Sulser T et al (2018) Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate 78:758\u2013765. https:\/\/doi.org\/10.1002\/pros.23522","journal-title":"Prostate"},{"key":"2118_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","volume":"8","author":"K L\u00fcckerath","year":"2018","unstructured":"L\u00fcckerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R et al (2018) Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res 8:96. https:\/\/doi.org\/10.1186\/s13550-018-0451-z","journal-title":"EJNMMI Res"},{"key":"2118_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/1078-0432.Ccr-16-0987","volume":"23","author":"RR McKay","year":"2017","unstructured":"McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z et al (2017) A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer. Clin Cancer Res 23:935\u2013945. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0987","journal-title":"Clin Cancer Res"},{"key":"2118_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"key":"2118_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging 47:9\u201315. https:\/\/doi.org\/10.1007\/s00259-019-04529-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2118_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071696","author":"F Rosar","year":"2022","unstructured":"Rosar F, Neher R, Burgard C, Linxweiler J, Schreckenberger M, Hoffmann MA et al (2022) Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14071696","journal-title":"Cancers (Basel)"},{"key":"2118_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/03915603241249230","volume":"91","author":"TB Cengiz","year":"2024","unstructured":"Cengiz TB, Kulkarni R, Novello M, Hafez A, Gavane S, Ghesani M et al (2024) Does enzalutamide related PSMA upregulation affect outcomes of lutetium-177 PSMA radioligand therapy? Urologia (Bologna) 91:525\u2013530. https:\/\/doi.org\/10.1177\/03915603241249230","journal-title":"Urologia (Bologna)"},{"key":"2118_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112691","author":"F Rosar","year":"2022","unstructured":"Rosar F, Bader H, Bartholom\u00e4 M, Maus S, Burgard C, Linxweiler J et al (2022) Addition of standard enzalutamide medication shows synergistic effects on response to [(177)Lu]Lu-PSMA-617 radioligand therapy in mCRPC patients with imminent treatment failure-preliminary evidence of pilot experience. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14112691","journal-title":"Cancers (Basel)"},{"key":"2118_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A et al (2019) Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 60:517\u2013523. https:\/\/doi.org\/10.2967\/jnumed.118.219352","journal-title":"J Nucl Med"},{"key":"2118_CR18","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1038\/s41467-021-25325-9","volume":"12","author":"C Kalogirou","year":"2021","unstructured":"Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmitz W, Wach S et al (2021) MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun 12:5066. https:\/\/doi.org\/10.1038\/s41467-021-25325-9","journal-title":"Nat Commun"},{"key":"2118_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787\u2013790. https:\/\/doi.org\/10.1126\/science.1168175","journal-title":"Science"},{"key":"2118_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","volume":"70","author":"MR Smith","year":"2016","unstructured":"Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G et al (2016) Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol 70:963\u2013970. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.023","journal-title":"Eur Urol"},{"key":"2118_CR21","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH et al (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 108:9578\u20139582. https:\/\/doi.org\/10.1073\/pnas.1106383108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2118_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R et al (2019) Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med 60:950\u2013954. https:\/\/doi.org\/10.2967\/jnumed.118.223099","journal-title":"J Nucl Med"},{"key":"2118_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118849","volume":"193","author":"F Devaux","year":"2025","unstructured":"Devaux F, Beltagi K, Ermler TF, Gerlach S, Herrmann A, Kranz J et al (2025) Androgen receptor blockade and its effect on PSMA-localization in prostate cancer: implications for radioligand therapy. Biomed Pharmacother 193:118849. https:\/\/doi.org\/10.1016\/j.biopha.2025.118849","journal-title":"Biomed Pharmacother"},{"key":"2118_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A et al (2024) [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 25:563\u2013571. https:\/\/doi.org\/10.1016\/s1470-2045(24)00135-9","journal-title":"Lancet Oncol"},{"key":"2118_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0145-8","volume":"5","author":"B Meller","year":"2015","unstructured":"Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L et al (2015) Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res 5:66. https:\/\/doi.org\/10.1186\/s13550-015-0145-8","journal-title":"EJNMMI Res"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02118-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02118-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02118-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T16:07:42Z","timestamp":1782058062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02118-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":25,"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02118-4","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}